{"analyses":[{"ciLowerLimit":"0.21","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.34","estimateComment":"A hazard ratio \\<1 favours AZD9291.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.27","statisticalComment":"Determined using a log rank test stratified by stage, race and mutation type.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Insufficient DFS events to estimate upper 95% confidence interval (Kaplan Meier analysis)","groupId":"OG000","lowerLimit":"61.7","upperLimit":"NA","value":"65.8"},{"groupId":"OG001","lowerLimit":"22.1","upperLimit":"35.0","value":"28.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"339"},{"groupId":"OG001","value":"343"}],"units":"Participants"}],"description":"Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence).","dispersionType":"95% Confidence Interval","groups":[{"description":"Taken once daily","id":"OG000","title":"AZD9291 80mg Tablet"},{"description":"Taken once daily","id":"OG001","title":"Placebo Tablet"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS) stage IB-IIIA patients","reportingStatus":"POSTED","timeFrame":"Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months)","title":"Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS).","type":"PRIMARY","unitOfMeasure":"Months"}